TickerTalks
Browse all tickers →
TickerTalks›$IBRX
IBIBRX

ImmunityBio, Inc.

$IBRX·$7.7B·Biotechnology·Healthcare
$7.80+6.6%YTD+257.4%1Y+161.6%
Mentions · last 7 days
2026-06-16: 264 posts2026-06-17: 298 posts2026-06-18: 241 posts2026-06-19: 78 posts2026-06-20: 32 posts2026-06-21: 60 posts2026-06-22: 151 posts1,136-10%
Price updated 8m ago·X counts updated 2d ago
IBIBRX
$IBRXImmunityBio, Inc.
$7.80+6.56%1.1k posts-10%
AI analysisFundamentalsVoices on X
Loading…

AI verdict & sentimentAI analysisGenerated by AI from underlying data

Top X posts

Today's AI verdict on what's driving $IBRX, plus how loud the X conversation is and which way it's leaning.

AI analysis

TickerTalks’ read on the fundamentals and what’s driving the move.

Hinges on a big eventWinding up for a moveAI verdict · as of 2026-06-24

Trading in a tight range and building pressure — a move looks likely soon, but the direction isn't clear yet.

ImmunityBio is sitting on a triple bottom around $6.90 with a 92%-utilization short setup, Russell 1000 inclusion in days, and a Saudi launch underway.

ImmunityBio is a clinical-stage immunotherapy company best known for ANKTIVA — its IL-15 superagonist approved for non-muscle-invasive bladder cancer. The stock has tripled year-to-date as the commercial launch broadens internationally, and the technical setup ahead of Russell 1000 inclusion is the cleanest part of the bundle.

  • The technical setup is the immediate catalyst: shares sit on a triple bottom near $6.90 with roughly 132 million shares short, ~92% short utilization, and roughly 80% of the float held by insiders — that's a textbook squeeze setup, with Russell 1000 inclusion on June 26 forcing passive demand on top.
  • The commercial story is genuinely scaling: Q1 2026 revenue grew 168% year over year to $44M with a 99% gross margin, and CEO Patrick Soon-Shiong has teased a July global-expansion announcement on the back of the recent Saudi Arabia commercial launch of ANKTIVA.
  • The supply chain is being locked down: ImmunityBio signed an exclusive 10-year development and supply agreement with Japan BCG Laboratory in mid-May for the Tokyo-172 BCG strain — a key commercial-enablement deal that removes a supply-chain risk ahead of broader US launch.
  • The bear case has real flags: an FDA warning letter in March on promotional claims and pending delays on the papillary NMIBC approval are the two unresolved items the skeptics keep flagging — both decide near-term commercial-launch pacing.
  • Insider activity is mostly governance: six directors each received 65,600-share awards at $7.25 on June 9, and director Barry Simon sold $165K — small dollars, consistent with a founder-controlled company.

A squeeze that resolves higher needs the June 26 Russell inclusion to deliver demand on top of the Soon-Shiong July global-expansion announcement — that combination at this short interest is the textbook setup. A meaningful disappointment on either side breaks the triple bottom and the coiling resolves lower.

Agrees with X sentimentX has the short-squeeze setup correctly framed — 132M shares short, 92% utilization, 80% insider-held, Russell 1000 inclusion plus the July global-expansion tease and ANKTIVA Saudi launch — and the bear flags around the March FDA warning letter and papillary NMIBC delays are the right caution.

What to watch: June 26 Russell 1000 inclusion plus the July global-expansion announcement from Patrick Soon-Shiong — a clean July reveal at this short interest restarts the move; a non-event July plus any negative FDA update on the papillary NMIBC indication breaks the triple bottom.

On the calendar: 2026-08-04 — Q2 2026 earnings

squeeze setupfda warning letter

X sentiment

What the X crowd is saying right now — descriptive, summarised from the day’s posts.

Bullish sentiment80 posts analyzed · as of 2026-06-23

ImmunityBio chatter is dominated by ANKTIVA's Saudi Arabia commercial launch, an upcoming July global-expansion announcement teased by Dr. Patrick Soon-Shiong on the Sean Spicer podcast, and the pending Russell 1000 reconstitution on June 26. Bulls hammer the short-squeeze setup, citing ~132M shares short, ~92% utilization, ~80% insider-held outstanding, and a triple bottom near $6.90, alongside lymphopenia and nanobody pipeline optionality. The bear/skeptic camp is small but vocal, flagging the FDA's March warning letter on promotional claims, FDA delays on papillary NMIBC approval, and frustration with sideways price action.

Read the AI verdict + X sentiment for $IBRX

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • X crowd read with bullish/bearish call + post volume
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Develops immunotherapy and cell therapy platforms targeting bladder, pancreatic, and lung cancers, plus infectious disease vaccines.

Industry overviewAI analysisGenerated by AI from underlying data

Where Biotechnology sits in its cycle right now — and what that implies for $IBRX.

Biotechnology · Healthcare

GLP-1 pipeline competition is the dominant structural driver — the ADA conference crystallized oral formulations, dual agonists, and differentiated mechanisms competing for a potential $150B obesity market by 2030. QURE's FDA accelerated approval for AMT-130 (Huntington's disease) this week confirms gene therapy regulatory momentum is still flowing capital to non-GLP-1 precision medicine.

What this means for $IBRX

Neutral — ImmunityBio's immunotherapy platforms for bladder and pancreatic cancers are in oncology with no GLP-1 or gene therapy structural driver exposure.

Top industry ETF

$IBBiShares Biotechnology ETF
+5.0%YTD
+42.5%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
-8.3How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
-44.5%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
-185%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
-4.1%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
51.4Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
139%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
93.8%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
-1.3Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q1 2026May 7, 2026$-0.09$-0.08-12.5%
Q4 2025Feb 23, 2026$-0.06$-0.08+25.0%
Q3 2025Nov 4, 2025$-0.07$-0.10+30.0%
Q2 2025Aug 5, 2025$-0.10$-0.100.0%
Next earningsTue, Aug 4·consensus EPS $-0.09

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q1 FY26$44.2M+167.6%99.5%-158%$-0.62$-77.1M
Q4 FY25$38.3M+407.0%88.9%-169%$-0.06$-71.2M
Q3 FY25$32.1M+425.1%87.1%-174%$-0.07$-69.7M
Q2 FY25$26.4M+2423.9%99.5%-270%$-0.10$-80.8M

Forward consensus

5-year forecast · up to 2 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$222.3M$195.9M – $248.8M-$0.85-$0.88 – -$0.812
FY27$452.0M$246.2M – $657.9M-$0.16-$0.38 – $0.072
FY28$1.4B$953.9M – $2.0B$0.54$0.31 – $0.841
FY29$2.3B$1.6B – $3.3B$0.95$0.55 – $1.471
FY30$3.1B$2.1B – $4.4B$1.41$0.82 – $2.181

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.0.7×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.50%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.-4.3%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.+39.9%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Insider activity

Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.

Recent transactions

SellJun 4Barry J. SimonDirector23.0K sh$165KSellFeb 24Barry J. SimonDirector75.0K sh$901KSellFeb 23Christobel SeleckyDirector25.0K sh$250KSellFeb 23Barry J. SimonDirector165.0K sh$1.7MSellFeb 20Barry J. SimonDirector10.0K sh$93KSellJan 20Christobel SeleckyDirector25.0K sh$188KSellJan 20Barry J. SimonDirector152.0K sh$1.1MSellJan 16Christobel SeleckyDirector50.0K sh$250K
+ 32 other (14 exempts · 11 inkinds · 6 awards · 1 conversion) in window

See when $IBRX insiders are putting their own money in

  • Real-time open-market buys and sells from Form 4 filings
  • Cluster-buy detection when multiple insiders pile in at once
  • 30 / 60 / 180-day windows so you can spot building conviction
Free, forever. No credit card.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

8-KShareholder voteJun 108-K — Item 5.07: Shareholder vote
AI summary

ImmunityBio, Inc. held its 2026 Annual Meeting on June 9, 2026, with approximately 85% of outstanding shares represented. Stockholders re-elected all nine incumbent directors (including founder/CEO Patrick Soon-Shiong) and ratified Deloitte & Touche LLP as auditor for fiscal 2026. Routine governance for a founder-controlled company; high participation rate reflects institutional engagement.

8-KMaterial agreementMay 188-K — Item 1.01: Material agreement · Item 7.01: Press release / Reg FD
AI summary

ImmunityBio, Inc. (IBRX) entered into an exclusive development and supply agreement with Japan BCG Laboratory (JBL) on May 14, 2026 for JBL to exclusively manufacture and supply the Tokyo-172 BCG strain for ImmunityBio's use in the U.S. and territories. ImmunityBio bears all development, clinical, and regulatory responsibilities for a 10-year initial term from FDA approval; no payments to JBL are due until approval, with at least 2 batches per year required post-approval. This agreement secures ImmunityBio's critical BCG supply chain ahead of anticipated commercial launch — a potentially material commercial enabler contingent on FDA approval.

8-KPress release / Reg FDApr 68-K — Item 7.01: Press release / Reg FD
AI summary

IBRX filed an 8-K Item 7.01 (Reg FD) disclosure dated 2026-04-06. Reg FD disclosures make material information simultaneously available to all investors; content may include guidance updates, strategic plans, or preliminary results.

8-KMaterial agreementMar 318-K — Item 1.01: Material agreement · Item 2.03: Material debt obligation · Item 7.01: Press release / Reg FD · Item 8.01: Other event
AI summary

IBRX entered into a amendment (8-K Item 1.01, dated 2026-03-31). Size: approximately $75.0 million. Material definitive agreement — investors should review the full exhibit for covenants, conditions, and use of proceeds.

SC 13D/AActivist amendmentFeb 25SC 13D/A
8-KMaterial agreementJan 268-K — Item 1.01: Material agreement
8-KMaterial agreementDec 29, 20258-K — Item 1.01: Material agreement · Item 8.01: Other event
424B5Prospectus supplement (offering)Dec 29, 2025424B5
+ 11 other (4 earnings 8-Ks · 2 proxys · 2 routine 8-Ks · 1 10-Q) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

ImmunityBio Presents New Clinical and Comparative Data Across Lung and Bladder Cancer at ASCO 2026gurufocus.com·23d agoImmunityBio Presents New Clinical and Comparative Data Across Lung and Bladder Cancer at ASCO 2026businesswire.com·23d agoIBRX and the BCG Shortage: Deals That Could Expand Demandzacks.com·26d agoImmunityBio: Anktiva Explained and What Comes Nextzacks.com·26d agoIBRX Stock Outlook After Q1 Results and a New FDA Reviewzacks.com·26d ago

In themes

Explore the broader themes this ticker is being talked about under.

AI Precision Medicine

More in Biotechnology

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$AURA$QURE$DFTX$ALLO$HUMA$ALT$APGE$PRAX
Voices on X · top 15 · last 7 days

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport